June 25 (Reuters) - The U.S. Centers for Disease Control

and Prevention's revamped vaccine advisory panel on Wednesday

postponed its vote on the use of respiratory syncytial virus

therapies to Thursday.

The panel, which has convened for a closely watched two-day

meeting, was discussing the use of AstraZeneca ( AZN ) and

Sanofi's Beyfortus and Merck's ( MRK ) Enflonsia.